170 related articles for article (PubMed ID: 36741014)
1. Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac.
Gao LR; Tian Y; Wang MS; Xia WL; Qin SR; Song YW; Wang SL; Tang Y; Fang H; Tang Y; Qi SN; Yan LL; Liu YP; Jing H; Chen B; Xing NZ; Li YX; Lu NN
Front Oncol; 2023; 13():1039901. PubMed ID: 36741014
[TBL] [Abstract][Full Text] [Related]
2. Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results.
Gao L; Wei R; Qin S; Tian Y; Xia W; Song Y; Wang S; Fang H; Tang Y; Jing H; Liu Y; Tang Y; Qi S; Chen B; Li Y; Xing N; Lu N
Chronic Dis Transl Med; 2024 Mar; 10(1):51-61. PubMed ID: 38450305
[TBL] [Abstract][Full Text] [Related]
3. Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac: clinical implementation and initial experience.
Intven MPW; de Mol van Otterloo SR; Mook S; Doornaert PAH; de Groot-van Breugel EN; Sikkes GG; Willemsen-Bosman ME; van Zijp HM; Tijssen RHN
Radiother Oncol; 2021 Jan; 154():172-178. PubMed ID: 32976875
[TBL] [Abstract][Full Text] [Related]
4. SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes.
Brennan VS; Burleson S; Kostrzewa C; Godoy Scripes P; Subashi E; Zhang Z; Tyagi N; Zelefsky MJ
Radiother Oncol; 2023 Feb; 179():109441. PubMed ID: 36549340
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of a sub-fractionation workflow for intrafraction re-planning during prostate radiotherapy treatment on a 1.5 Tesla MR-Linac: A practical method to mitigate intrafraction motion.
Willigenburg T; Zachiu C; Bol GH; de Groot-van Beugel EN; Lagendijk JJW; van der Voort van Zyp JRN; Raaymakers BW; de Boer JCJ
Radiother Oncol; 2022 Nov; 176():25-30. PubMed ID: 36113777
[TBL] [Abstract][Full Text] [Related]
6. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation.
Potkrajcic V; Gani C; Fischer SG; Boeke S; Niyazi M; Thorwarth D; Voigt O; Schneider M; Mönnich D; Kübler S; Boldt J; Hoffmann E; Paulsen F; Mueller AC; Wegener D
Curr Oncol; 2024 May; 31(5):2679-2688. PubMed ID: 38785484
[TBL] [Abstract][Full Text] [Related]
7. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac.
de Muinck Keizer DM; Kerkmeijer LGW; Willigenburg T; van Lier ALHMW; Hartogh MDD; van der Voort van Zyp JRN; de Groot-van Breugel EN; Raaymakers BW; Lagendijk JJW; de Boer JCJ
Radiother Oncol; 2020 Oct; 151():88-94. PubMed ID: 32622779
[TBL] [Abstract][Full Text] [Related]
8. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
Chuong MD; Clark MA; Henke LE; Kishan AU; Portelance L; Parikh PJ; Bassetti MF; Nagar H; Rosenberg SA; Mehta MP; Refaat T; Rineer JM; Smith A; Seung S; Zaki BI; Fuss M; Mak RH
Clin Transl Radiat Oncol; 2023 Jan; 38():161-168. PubMed ID: 36466748
[TBL] [Abstract][Full Text] [Related]
9. Adaptive SBRT by 1.5 T MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time.
Ruggieri R; Rigo M; Naccarato S; Gurrera D; Figlia V; Mazzola R; Ricchetti F; Nicosia L; Giaj-Levra N; Cuccia F; Vitale C; Stavreva N; Pressyanov DS; Stavrev P; Pellegrini R; Alongi F
Phys Med; 2020 Dec; 80():34-41. PubMed ID: 33091796
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric comparison of automatically propagated prostate contours with manually drawn contours in MRI-guided radiotherapy: A step towards a contouring free workflow?
Sritharan K; Dunlop A; Mohajer J; Adair-Smith G; Barnes H; Brand D; Greenlay E; Hijab A; Oelfke U; Pathmanathan A; Mitchell A; Murray J; Nill S; Parker C; Sundahl N; Tree AC
Clin Transl Radiat Oncol; 2022 Nov; 37():25-32. PubMed ID: 36052018
[TBL] [Abstract][Full Text] [Related]
11. First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac.
Wegener D; Thome A; Paulsen F; Gani C; Boldt J; Butzer S; Thorwarth D; Moennich D; Nachbar M; Müller AC; Zips D; Boeke S
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36012885
[TBL] [Abstract][Full Text] [Related]
12. Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-Linac.
Muinck Keizer DM; Willigenburg T; der Voort van Zyp JRN; Raaymakers BW; Lagendijk JJW; Boer JCJ
Radiother Oncol; 2021 Sep; 162():162-169. PubMed ID: 34293410
[TBL] [Abstract][Full Text] [Related]
13. Automatic reconstruction of the delivered dose of the day using MR-linac treatment log files and online MR imaging.
Menten MJ; Mohajer JK; Nilawar R; Bertholet J; Dunlop A; Pathmanathan AU; Moreau M; Marshall S; Wetscherek A; Nill S; Tree AC; Oelfke U
Radiother Oncol; 2020 Apr; 145():88-94. PubMed ID: 31931291
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows.
Hassan SP; de Leon J; Batumalai V; Moutrie Z; Hogan L; Ge Y; Stricker P; Jameson MG
J Appl Clin Med Phys; 2024 Apr; 25(4):e14253. PubMed ID: 38394627
[TBL] [Abstract][Full Text] [Related]
15. Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation.
Boekhoff MR; Bouwmans R; Doornaert PAH; Intven MPW; Lagendijk JJW; van Lier ALHMW; Rasing MJA; van de Ven S; Meijer GJ; Mook S
Clin Transl Radiat Oncol; 2022 May; 34():82-89. PubMed ID: 35372703
[TBL] [Abstract][Full Text] [Related]
16. Impact of daily plan adaptation on accumulated doses in ultra-hypofractionated magnetic resonance-guided radiation therapy of prostate cancer.
Xiong Y; Rabe M; Rippke C; Kawula M; Nierer L; Klüter S; Belka C; Niyazi M; Hörner-Rieber J; Corradini S; Landry G; Kurz C
Phys Imaging Radiat Oncol; 2024 Jan; 29():100562. PubMed ID: 38463219
[TBL] [Abstract][Full Text] [Related]
17. Utilization of cone-beam CT for offline evaluation of target volume coverage during prostate image-guided radiotherapy based on bony anatomy alignment.
Paluska P; Hanus J; Sefrova J; Rouskova L; Grepl J; Jansa J; Kasaova L; Hodek M; Zouhar M; Vosmik M; Petera J
Rep Pract Oncol Radiother; 2012; 17(3):134-40. PubMed ID: 24377014
[TBL] [Abstract][Full Text] [Related]
18. Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial.
Cao M; Gao Y; Yoon SM; Yang Y; Sheng K; Ballas LK; Basehart V; Sachdeva A; Felix C; Low DA; Steinberg ML; Kishan AU
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199881
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric Evaluation of Incorporating Patient Geometric Variations Into Adaptive Plan Optimization Through Probabilistic Treatment Planning in Head and Neck Cancers.
Liu Q; Liang J; Zhou D; Krauss DJ; Chen PY; Yan D
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):985-997. PubMed ID: 29976511
[TBL] [Abstract][Full Text] [Related]
20. Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study.
Willigenburg T; Beld E; Hes J; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN
Phys Imaging Radiat Oncol; 2020 Jul; 15():60-65. PubMed ID: 33458327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
